United Kingdom

People: Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

18 Sep 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hopfield, Jessica 

Dr. Jessica Hopfield is a Independent Director of the Company. Dr. Hopfield has served on the board of directors of Insulet Corporation, a public medical device company ("Insulet"), since July 2015 and as its lead independent director from August 2016 until January 2019 and on the board of directors of Radius Health, Inc., a public biopharmaceutical company, since January 2019. In October 2015, Dr. Hopfield was appointed, and currently serves, as Chairperson of the Board of Trustees of the Joslin Diabetes Center. From 2013 to October 2015, Dr. Hopfield served as the Vice Chair of the Board of Trustees of the Joslin Diabetes Center. Since 2010, Dr. Hopfield has been the principal at J Hopfield Consulting providing guidance and executive coaching to start-up technology firms. From 1995 to 2009, Dr. Hopfield was a Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice and she served clients across pharmaceutical, biotechnology, medical device and consumer industries with a focus on strategy, R&D management, and marketing. Dr. Hopfield also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing, and served on the board of rEVO Biologics, a private company. Dr. Hopfield earned a B.S. from Yale College, an M.B.A. from Harvard Graduate School of Business Administration as a Baker Scholar, and a Ph.D. in Neuroscience/Biochemistry from The Rockefeller University. We believe that Dr. Hopfield's executive and consulting experience in the healthcare, pharmaceutical, and medical device industries qualifies her to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, USD 43,281
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 564,917
Fiscal Year Total, USD 608,198

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Mullen


Cynthia Collins


Eric Ek


Vickesh Myer


Charles Albright


Katrine Bosley

As Of  31 Dec 2018